Figure 3From: Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis Response gain distribution in control group (a) and bevacizumab plus irinotecan group (b). The combination of bevacizumab and irinotecan showed benefit in treatment response for patients with recurrent HGG.Back to article page